{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:11:07Z","timestamp":1792782667093,"version":"4.5.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Consiglio Nazionale Delle Ricerche","id":[{"id":"https:\/\/ror.org\/04zaypm56","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Purpose<\/jats:title>\n                    <jats:p>Lung cancer is the most frequently diagnosed malignancy worldwide in recent decades, representing the leading cause of cancer-related mortality globally. Lung cancer is mainly divided into two types, non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with NSCLC being the most common, representing about 85% of cases. NSCLC is increasingly recognized to harbor various druggable genetic alterations; among them, activating BRAF mutations are found in approximately 3\u20134% of NSCLC patients. The objective of this review is to provide a comprehensive overview of the key biological and pathophysiological characteristics of BRAF molecular alterations, their impact on clinical practice, and emerging insights from translational research.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a search of the PubMed database on April 22, 2026. A review of retrieved literature related to BRAF mutations and their clinical implications in NSCLC was completed. The Catalogue of Somatic Mutation in Cancer (COSMIC) database and the NCCN-NSCLC Guidelines were evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Functional classification of BRAF genetic alterations, molecular assays for detection of BRAF gene mutation, advancements of targeted therapies and immunotherapy for BRAF\u2011mutant NSCLC, and treatment resistance mechanisms were described. Several ongoing studies currently evaluating novel agents with broader biological activity and various drug combinations were reported. Emerging strategies\u2014including next-generation MAPK inhibitors, ADCs, and engineered cellular therapies\u2014were discussed, offering promising avenues to enhance efficacy, overcome resistance, and expand therapeutic options for these patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Despite limited clinical data, particularly in first line and neoadjuvant settings, remain major challenges, addressing critical questions will be useful to optimize the management of BRAF-mutant NSCLC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00408-026-00932-9","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:58:34Z","timestamp":1789549114000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Unveiling BRAF Mutations in Non-small Cell Lung Cancer: State of the Art and Future Perspectives"],"prefix":"10.1007","volume":"204","author":[{"given":"Maria","family":"Colombino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Paliogiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grazia","family":"Palomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Pisano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Casula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro Giuseppe","family":"Fois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Zinellu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Palmieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"932_CR1","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/2049-6958-8-45","volume":"8","author":"P Paliogiannis","year":"2013","unstructured":"Paliogiannis P, Attene F, Cossu A et al (2013) Lung cancer epidemiology in North Sardinia, Italy. Multidiscip Respir Med 8:45. https:\/\/doi.org\/10.1186\/2049-6958-8-45","journal-title":"Multidiscip Respir Med"},{"key":"932_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"932_CR3","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.3390\/cancers16152643","volume":"16","author":"F Siddique","year":"2024","unstructured":"Siddique F, Shehata M, Ghazal M et al (2024) Lung cancer subtyping: a short review. Cancers (Basel) 16:2643. https:\/\/doi.org\/10.3390\/cancers16152643","journal-title":"Cancers (Basel)"},{"issue":"Suppl 4","key":"932_CR4","doi-asserted-by":"publisher","first-page":"S389","DOI":"10.3978\/j.issn.2072-1439.2013.07.10","volume":"4","author":"K Zarogoulidis","year":"2013","unstructured":"Zarogoulidis K, Zarogoulidis P, Darwiche K et al (2013) Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis 5 Suppl 4(Suppl 4):S389\u2013S396. https:\/\/doi.org\/10.3978\/j.issn.2072-1439.2013.07.10","journal-title":"J Thorac Dis 5 Suppl"},{"key":"932_CR5","doi-asserted-by":"publisher","first-page":"104752","DOI":"10.1016\/j.compbiomed.2021.104752","volume":"136","author":"Z Khodabakhshi","year":"2021","unstructured":"Khodabakhshi Z, Mostafaei S, Arabi H et al (2021) Non-small cell lung carcinoma histopathological subtype phenotyping using high-dimensional multinomial multiclass CT radiomics signature. Comput Biol Med 136:104752. https:\/\/doi.org\/10.1016\/j.compbiomed.2021.104752","journal-title":"Comput Biol Med"},{"issue":"7511","key":"932_CR6","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nature13385","volume":"511","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network (2014) Comprehensive molecular profiling of lung adenocarcinoma. Nature 511(7511):543\u2013550.https:\/\/doi.org\/10.1038\/nature13385","journal-title":"Nature"},{"key":"932_CR7","doi-asserted-by":"publisher","first-page":"a037812","DOI":"10.1101\/cshperspect.a037812","volume":"12","author":"J Saller","year":"2022","unstructured":"Saller J, Boyle J TA (2022) Molecular pathology of lung cancer. Cold Spring Harb Perspect Med 12:a037812. https:\/\/doi.org\/10.1101\/cshperspect.a037812","journal-title":"Cold Spring Harb Perspect Med"},{"key":"932_CR8","doi-asserted-by":"publisher","first-page":"415","DOI":"10.17179\/excli2023-6122","volume":"22","author":"A Grodzka","year":"2023","unstructured":"Grodzka A, Knopik-Skrocka A, Kowalska K et al (2023) Molecular alterations of driver genes in non-small cell lung cancer: from diagnostics to targeted therapy. EXCLI J 22:415\u2013432. https:\/\/doi.org\/10.17179\/excli2023-6122","journal-title":"EXCLI J"},{"key":"932_CR9","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13073-022-01089-9","volume":"14","author":"Q Li","year":"2022","unstructured":"Li Q, Wang R, Yang Z et al (2022) Molecular profiling of human non-small cell lung cancer by single-cell RNA-seq. Genome Med 14:87. https:\/\/doi.org\/10.1186\/s13073-022-01089-9","journal-title":"Genome Med"},{"key":"932_CR10","doi-asserted-by":"publisher","first-page":"108550","DOI":"10.1016\/j.lungcan.2025.108550","volume":"204","author":"R Serna-Blasco","year":"2025","unstructured":"Serna-Blasco R, Mediavilla-Medel P, Medina K et al (2025) Comprehensive molecular profiling of advanced NSCLC using NGS: Prevalence of druggable mutations and clinical trial opportunities in the ATLAS study. Lung Cancer 204:108550. https:\/\/doi.org\/10.1016\/j.lungcan.2025.108550","journal-title":"Lung Cancer"},{"key":"932_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.lungcan.2021.02.026","volume":"154","author":"KM Kerr","year":"2021","unstructured":"Kerr KM, Bibeau F, Thunnissen E et al (2021) The evolving landscape of biomarker testing for non-small cell lung cancer in Europe. Lung Cancer 154:161\u2013175. https:\/\/doi.org\/10.1016\/j.lungcan.2021.02.026","journal-title":"Lung Cancer"},{"key":"932_CR12","doi-asserted-by":"publisher","first-page":"104925","DOI":"10.1016\/j.critrevonc.2025.104925","volume":"215","author":"M Colombino","year":"2025","unstructured":"Colombino M, Palomba G, Casula M et al (2025) KRAS mutations in non-small cell lung cancer: Translational aspects, current therapies and challenges for future research. Crit Rev Oncol Hematol 215:104925. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104925","journal-title":"Crit Rev Oncol Hematol"},{"key":"932_CR13","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3390\/ijms22020612","volume":"22","author":"SS Fois","year":"2021","unstructured":"Fois SS, Paliogiannis P, Zinellu A et al (2021) Molecular epidemiology of the main druggable genetic alterations in non-small cell lung Ccncer. Int J Mol Sci 22:612. https:\/\/doi.org\/10.3390\/ijms22020612","journal-title":"Int J Mol Sci"},{"key":"932_CR14","doi-asserted-by":"publisher","first-page":"104217","DOI":"10.1016\/j.critrevonc.2023.104217","volume":"193","author":"U Malapelle","year":"2024","unstructured":"Malapelle U, Donne AD, Pagni F et al (2024) Standardized and simplified reporting of next-generation sequencing results in advanced non-small-cell lung cancer: practical indications from an Italian multidisciplinary group. Crit Rev Oncol Hematol 193:104217. https:\/\/doi.org\/10.1016\/j.critrevonc.2023.104217","journal-title":"Crit Rev Oncol Hematol"},{"key":"932_CR15","doi-asserted-by":"publisher","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","volume":"142","author":"NI Lindeman","year":"2018","unstructured":"Lindeman NI, Cagle PT, Aisner DL et al (2018) Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med 142:321\u2013346. https:\/\/doi.org\/10.5858\/arpa.2017-0388-CP","journal-title":"Arch Pathol Lab Med"},{"key":"932_CR16","doi-asserted-by":"publisher","first-page":"354","DOI":"10.6004\/jnccn.2025.0043","volume":"23","author":"GJ Riely","year":"2025","unstructured":"Riely GJ, Wood DE, Aisner DL et al (2025) NCCN Guidelines\u00ae Insights: Non-Small Cell Lung Cancer, Version 7.2025. J Natl Compr Canc Netw 23:354\u2013362. https:\/\/doi.org\/10.6004\/jnccn.2025.0043","journal-title":"J Natl Compr Canc Netw"},{"key":"932_CR17","doi-asserted-by":"publisher","first-page":"689","DOI":"10.3390\/cancers15030689","volume":"15","author":"C Putzu","year":"2023","unstructured":"Putzu C, Canova S, Paliogiannis P et al (2023) Duration of immunotherapy in non-small cell lung cancer survivors: A lifelong commitment? Cancers (Basel) 15:689. https:\/\/doi.org\/10.3390\/cancers15030689","journal-title":"Cancers (Basel)"},{"key":"932_CR18","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1097\/CJI.0000000000000500","volume":"47","author":"KG Akers","year":"2024","unstructured":"Akers KG, Oskar S, Zhao B et al (2024) Clinical outcomes of PD-1\/PD-L1 inhibitors among patients with advanced or metastatic non-small cell lung cancer with BRAF, ERBB2\/HER2, MET, or RET alterations: A systematic literature review. J Immunother 47:128\u2013138. https:\/\/doi.org\/10.1097\/CJI.0000000000000500","journal-title":"J Immunother"},{"issue":"1","key":"932_CR19","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s12890-021-01803-0","volume":"22","author":"P Paliogiannis","year":"2022","unstructured":"Paliogiannis P, Colombino M, Sini MC et al (2022) Global prognostic impact of driver genetic alterations in patients with lung adenocarcinoma: a real-life study. BMC Pulm Med 22(1):32. https:\/\/doi.org\/10.1186\/s12890-021-01803-0","journal-title":"BMC Pulm Med"},{"issue":"1","key":"932_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1186\/s12890-019-0964-x","volume":"19","author":"M Colombino","year":"2019","unstructured":"Colombino M, Paliogiannis P, Cossu A et al (2019) EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma. BMC Pulm Med 19(1):209. https:\/\/doi.org\/10.1186\/s12890-019-0964-x","journal-title":"BMC Pulm Med"},{"key":"932_CR21","doi-asserted-by":"publisher","first-page":"1514653","DOI":"10.3389\/fonc.2025.1514653","volume":"15","author":"X Feng","year":"2025","unstructured":"Feng X, Zeng R, Lyu M et al (2025) Clinical and molecular characteristics, therapeutic strategies, and prognosis of non-small cell lung cancer patients harboring primary and acquired BRAF mutations. Front Oncol 15:1514653. https:\/\/doi.org\/10.3389\/fonc.2025.1514653","journal-title":"Front Oncol"},{"issue":"6892","key":"932_CR22","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C et al (2002) Mutations of the BRAF gene in human cancer. Nature 417(6892):949\u2013954. https:\/\/doi.org\/10.1038\/nature00766","journal-title":"Nature"},{"key":"932_CR23","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1177\/1947601911407323","volume":"2","author":"D Matallanas","year":"2011","unstructured":"Matallanas D, Birtwistle M, Romano D et al (2011) Raf family kinases: old dogs have learned new tricks. Genes Cancer 2:232\u2013260. https:\/\/doi.org\/10.1177\/1947601911407323","journal-title":"Genes Cancer"},{"key":"932_CR24","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1128\/MCB.26.6.2262-2272.2006","volume":"26","author":"LK Rushworth","year":"2006","unstructured":"Rushworth LK, Hindley AD, O\u2019Neill E et al (2006) Mol Cell Biol 26:2262\u20132272. https:\/\/doi.org\/10.1128\/MCB.26.6.2262-2272.2006","journal-title":"Mol Cell Biol"},{"key":"932_CR25","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/nrc1503","volume":"4","author":"JS Sebolt-Leopold","year":"2004","unstructured":"Sebolt-Leopold JS, Herrera R (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4:937\u2013947.https:\/\/doi.org\/10.1038\/nrc1503","journal-title":"Nat Rev Cancer"},{"key":"932_CR26","doi-asserted-by":"publisher","first-page":"110","DOI":"10.3978\/j.issn.2218-6751.2015.01.01","volume":"4","author":"CN Prabhakar","year":"2015","unstructured":"Prabhakar CN (2015) Epidermal growth factor receptor in non-small cell lung cancer. Transl Lung Cancer Res 4:110\u2013118. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2015.01.01","journal-title":"Transl Lung Cancer Res"},{"issue":"6","key":"932_CR27","first-page":"691","volume":"2","author":"JY Zhang","year":"2012","unstructured":"Zhang JY, Selim MA (2012) The role of the c-Jun N-terminal Kinase signaling pathway in skin cancer. Am J Cancer Res 2(6):691\u2013698","journal-title":"Am J Cancer Res"},{"key":"932_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/s0092-8674(04)00215-6","author":"PT Wan","year":"2004","unstructured":"Wan PT, Garnett MJ, Roe SM et al (2004) Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. https:\/\/doi.org\/10.1016\/s0092-8674(04)00215-6. 116:855\u2009\u2013\u200967","journal-title":"Cell"},{"key":"932_CR29","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrc3760","volume":"14","author":"M Holderfield","year":"2014","unstructured":"Holderfield M, Deuker MM, McCormick F et al (2014) Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond. Nat Rev Cancer 14:455\u2013467. https:\/\/doi.org\/10.1038\/nrc3760","journal-title":"Nat Rev Cancer"},{"key":"932_CR30","doi-asserted-by":"publisher","first-page":"103118","DOI":"10.1016\/j.critrevonc.2020.103118","volume":"156","author":"U Malapelle","year":"2020","unstructured":"Malapelle U, Rossi G, Pisapia P et al (2020) BRAF as a positive predictive biomarker: Focus on lung cancer and melanoma patients. Crit Rev Oncol Hematol 156:103118. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103118","journal-title":"Crit Rev Oncol Hematol"},{"key":"932_CR31","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.21037\/tlcr-24-253","volume":"13","author":"I Chmielewska","year":"2024","unstructured":"Chmielewska I, Krawczyk P, W\u00f3jcik-Superczy\u0144ska M et al (2024) Exploring immunotherapy efficacy in non-small cell lung cancer patients with BRAF mutations: a case series and literature review. Transl Lung Cancer Res 13:2491\u20132499. https:\/\/doi.org\/10.21037\/tlcr-24-253","journal-title":"Transl Lung Cancer Res"},{"key":"932_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/cncr.35781","volume":"131","author":"C Parisi","year":"2025","unstructured":"Parisi C, Planchard D (2025) BRAF in non-small cell lung cancer: from molecular mechanisms to clinical practice. Cancer 131: Suppl 1e3578110. https:\/\/doi.org\/10.1002\/cncr.35781","journal-title":"Cancer"},{"key":"932_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2009.04.001","author":"N Dhomen","year":"2009","unstructured":"Dhomen N, Marais R (2009) BRAF signaling and targeted therapies in melanoma. Hematol Oncol Clin North Am. https:\/\/doi.org\/10.1016\/j.hoc.2009.04.001. 23:529\u2009\u2013\u200945","journal-title":"Hematol Oncol Clin North Am"},{"key":"932_CR34","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/sj.bjc.6606030","volume":"104","author":"HT Arkenau","year":"2011","unstructured":"Arkenau HT, Kefford R, Long GV (2011) Targeting BRAF for patients with melanoma. Br J Cancer 104:392\u2013398. https:\/\/doi.org\/10.1038\/sj.bjc.6606030","journal-title":"Br J Cancer"},{"key":"932_CR35","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/1535370220959657","volume":"246","author":"J Owsley","year":"2021","unstructured":"Owsley J, Stein MK, Porter J et al (2021) Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database. Exp Biol Med (Maywood) 246:31\u201339. https:\/\/doi.org\/10.1177\/1535370220959657","journal-title":"Exp Biol Med (Maywood)"},{"key":"932_CR36","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1002\/ijc.29825","volume":"138","author":"JS Ross","year":"2016","unstructured":"Ross JS, Wang K, Chmielecki J et al (2016) The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int J Cancer 138:881\u2013890. https:\/\/doi.org\/10.1002\/ijc.29825","journal-title":"Int J Cancer"},{"key":"932_CR37","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1016\/j.ccell.2015.08.001","volume":"28","author":"Z Yao","year":"2015","unstructured":"Yao Z, Torres NM, Tao A et al (2015) BRAF mutants evade ERK-dependent feedback by different mechanisms that determine their sensitivity to pharmacologic inhibition. Cancer Cell 28:370\u2013383. https:\/\/doi.org\/10.1016\/j.ccell.2015.08.001","journal-title":"Cancer Cell"},{"key":"932_CR38","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nature23291","volume":"548","author":"Z Yao","year":"2017","unstructured":"Yao Z, Yaeger R, Rodrik-Outmezguine VS et al (2017) Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature 548:234\u2013238. https:\/\/doi.org\/10.1038\/nature23291","journal-title":"Nature"},{"key":"932_CR39","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1038\/s41388-018-0171-x","volume":"37","author":"M Dankner","year":"2018","unstructured":"Dankner M, Rose AAN, Rajkumar S et al (2018) Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations. Oncogene 37:3183\u20133199. https:\/\/doi.org\/10.1038\/s41388-018-0171-x","journal-title":"Oncogene"},{"key":"932_CR40","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.3390\/cancers11091381","volume":"11","author":"JWP Bracht","year":"2019","unstructured":"Bracht JWP, Karachaliou N, Bivona T et al (2019) BRAF mutations classes I, II, and III in NSCLC patients included in the SLLIP trial: The need for a new pre-clinical treatment rationale. Cancers (Basel) 11:1381. https:\/\/doi.org\/10.3390\/cancers11091381","journal-title":"Cancers (Basel)"},{"key":"932_CR41","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1158\/2159-8290.CD-18-1321","volume":"9","author":"R Yaeger","year":"2019","unstructured":"Yaeger R, Corcoran RB et al (2019) Targeting alterations in the RAF-MEK pathway. Cancer Discov 9:329\u2013341. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1321","journal-title":"Cancer Discov"},{"key":"932_CR42","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1158\/1078-0432.CCR-18-2062","volume":"25","author":"I Dagogo-Jack","year":"2019","unstructured":"Dagogo-Jack I, Martinez P, Yeap BY et al (2019) Impact of BRAF mutation class on disease characteristics and clinical outcomes in BRAF-mutant lung cancer. Clin Cancer Res 25:158\u2013165. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2062","journal-title":"Clin Cancer Res"},{"key":"932_CR43","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1158\/2159-8290.CD-15-0896","volume":"6","author":"SH Chen","year":"2016","unstructured":"Chen SH, Zhang Y, Van Horn RD et al (2016) Oncogenic BRAF deletions that function as homodimers and are sensitive to inhibition by RAF dimer inhibitor LY3009120. Cancer Discov 6:300\u2013315. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0896","journal-title":"Cancer Discov"},{"key":"932_CR44","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1111\/pcmr.12674","volume":"31","author":"DB Johnson","year":"2018","unstructured":"Johnson DB, Childress MA, Chalmers ZR et al (2018) BRAF internal deletions and resistance to BRAF\/MEK inhibitor therapy. Pigment Cell Melanoma Res 31:432\u2013436. https:\/\/doi.org\/10.1111\/pcmr.12674","journal-title":"Pigment Cell Melanoma Res"},{"key":"932_CR45","doi-asserted-by":"publisher","unstructured":"Kim HS, Jung M, Kang HN et al. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK\/PI3K inhibition or MEK\/CDK4\/6 inhibition. Oncogene 36:3334\u20133345. https:\/\/doi.org\/10.1038\/onc.2016.486","DOI":"10.1038\/onc.2016.486"},{"key":"932_CR46","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.jtho.2018.12.038","volume":"14","author":"M Vojnic","year":"2019","unstructured":"Vojnic M, Kubota D, Kurzatkowski C et al (2019) Acquired BRAF rearrangements induce secondary resistance to EGFR therapy in EGFR-mutated lung cancers. J Thorac Oncol 14:802\u2013815. https:\/\/doi.org\/10.1016\/j.jtho.2018.12.038","journal-title":"J Thorac Oncol"},{"key":"932_CR47","doi-asserted-by":"publisher","first-page":"460","DOI":"10.3892\/mco.2018.1555","volume":"8","author":"S Trubini","year":"2018","unstructured":"Trubini S, Ubiali A, Paties CT et al (2018) Novel BRAF mutation in melanoma: a case report. Mol Clin Oncol 8:460\u2013462. https:\/\/doi.org\/10.3892\/mco.2018.1555","journal-title":"Mol Clin Oncol"},{"key":"932_CR48","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s11864-021-00827-2","volume":"22","author":"BR Halle","year":"2021","unstructured":"Halle BR, Johnson DB (2021) Defining and targeting BRAF mutations in solid tumors. Curr Treat Options Oncol 22:30. https:\/\/doi.org\/10.1007\/s11864-021-00827-2","journal-title":"Curr Treat Options Oncol"},{"key":"932_CR49","unstructured":"ANON Catalogue of Somatic Mutation in Cancer\/COSMIC version 90 (2009) https:\/\/cosmic-blog.sanger.ac.uk\/cosmic-release-v90. Accessed 22 April 2026"},{"key":"932_CR50","doi-asserted-by":"publisher","first-page":"104435","DOI":"10.1016\/j.critrevonc.2024.104435","volume":"201","author":"M Colombino","year":"2024","unstructured":"Colombino M, Casula M, Paliogiannis P et al (2024) Heterogeneous pathogenesis of melanoma: BRAF mutations and beyond. Crit Rev Oncol Hematol 201:104435. https:\/\/doi.org\/10.1016\/j.critrevonc.2024.104435","journal-title":"Crit Rev Oncol Hematol"},{"key":"932_CR51","unstructured":"cBioPortal For Cancer Studies (2026) https:\/\/www.cbioportal.org. Accessed 22 April"},{"key":"932_CR52","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1093\/jnci\/95.8.625","volume":"95","author":"Y Cohen","year":"2003","unstructured":"Cohen Y, Xing M, Mambo E et al (2003) BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 95:625\u2013627. https:\/\/doi.org\/10.1093\/jnci\/95.8.625","journal-title":"J Natl Cancer Inst"},{"key":"932_CR53","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.2741\/4359","volume":"20","author":"DD Li","year":"2015","unstructured":"Li DD, Zhang YF, Xu HX et al (2015) The role of BRAF in the pathogenesis of thyroid carcinoma. Front Biosci (Landmark Ed) 20:1068\u20131078. https:\/\/doi.org\/10.2741\/4359","journal-title":"Front Biosci (Landmark Ed)"},{"key":"932_CR54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/CCO.0000000000000797","volume":"34","author":"RS Scheffel","year":"2022","unstructured":"Scheffel RS, Dora JM, Maia AL (2022) BRAF mutations in thyroid cancer. Curr Opin Oncol 34:9\u201318. https:\/\/doi.org\/10.1097\/CCO.0000000000000797","journal-title":"Curr Opin Oncol"},{"key":"932_CR55","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.jmoldx.2012.10.002","volume":"15","author":"WO Greaves","year":"2013","unstructured":"Greaves WO, Verma S, Patel KP et al (2013) Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn 15:220\u2013226. https:\/\/doi.org\/10.1016\/j.jmoldx.2012.10.002","journal-title":"J Mol Diagn"},{"key":"932_CR56","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.ejca.2011.06.056","volume":"48","author":"L Si","year":"2012","unstructured":"Si L, Kong Y, Xu X et al (2012) Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort. Eur J Cancer 48:94\u2013100. https:\/\/doi.org\/10.1016\/j.ejca.2011.06.056","journal-title":"Eur J Cancer"},{"key":"932_CR57","doi-asserted-by":"publisher","first-page":"7","DOI":"10.32604\/or.2025.071831","volume":"34","author":"S Dore","year":"2026","unstructured":"Dore S, Sacchi M, Pinna A et al (2026) Clinical molecular pathology and treatment developments in advanced uveal melanoma: state of the art. Oncol Res 34:7. https:\/\/doi.org\/10.32604\/or.2025.071831","journal-title":"Oncol Res"},{"key":"932_CR58","doi-asserted-by":"publisher","first-page":"e13160","DOI":"10.1111\/ecc.13160","volume":"28","author":"M Moosazadeh","year":"2019","unstructured":"Moosazadeh M, Sadough A, Afshari M et al (2019) Prevalence of BRAF gene mutation in samples of primary and metastatic colorectal cancer: a meta-analysis. Eur J Cancer Care (Engl) 28:e13160. https:\/\/doi.org\/10.1111\/ecc.13160","journal-title":"Eur J Cancer Care (Engl)"},{"key":"932_CR59","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1038\/bjc.2015.160","volume":"112","author":"TT Sepp\u00e4l\u00e4","year":"2015","unstructured":"Sepp\u00e4l\u00e4 TT, B\u00f6hm JP, Friman M et al (2015) Combination of microsatellite instability and BRAF mutation status for subtyping colorectal cancer. Br J Cancer 112:1966\u20131975.https:\/\/doi.org\/10.1038\/bjc.2015.160","journal-title":"Br J Cancer"},{"key":"932_CR60","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","volume":"364","author":"E Tiacci","year":"2011","unstructured":"Tiacci E, Trifonov V, Schiavoni G et al (2011) BRAF mutations in hairy-cell leukemia. N Engl J Med 364:2305\u20132315. https:\/\/doi.org\/10.1056\/NEJMoa1014209","journal-title":"N Engl J Med"},{"key":"932_CR61","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1016\/j.jtho.2020.05.021","volume":"15","author":"MV Negrao","year":"2020","unstructured":"Negrao MV, Raymond VM, Lanman RB et al (2020) Molecular landscape of BRAF-mutant NSCLC reveals an association between clonality and driver mutations and identifies targetable non-V600 driver mutations. J Thorac Oncol 15:1611\u20131623. https:\/\/doi.org\/10.1016\/j.jtho.2020.05.021","journal-title":"J Thorac Oncol"},{"key":"932_CR62","doi-asserted-by":"publisher","first-page":"863043","DOI":"10.3389\/fonc.2022.863043","volume":"12","author":"N Yan","year":"2022","unstructured":"Yan N, Guo S, Zhang H et al (2022) BRAF-mutated non-small cell lung cancer: current treatment status and future perspective. Front Oncol 12:863043. https:\/\/doi.org\/10.3389\/fonc.2022.863043","journal-title":"Front Oncol"},{"key":"932_CR63","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s12967-019-2036-7","volume":"17","author":"Q Lin","year":"2019","unstructured":"Lin Q, Zhang H, Ding H et al (2019) The association between BRAF mutation class and clinical features in BRAF-mutant Chinese non-small cell lung cancer patients. J Transl Med 17:298. https:\/\/doi.org\/10.1186\/s12967-019-2036-7","journal-title":"J Transl Med"},{"key":"932_CR64","doi-asserted-by":"publisher","first-page":"e40109","DOI":"10.1371\/journal.pone.0040109","volume":"7","author":"SJ An","year":"2012","unstructured":"An SJ, Chen ZH, Su J et al (2012) Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status. PLoS ONE 7:e40109. https:\/\/doi.org\/10.1371\/journal.pone.0040109","journal-title":"PLoS ONE"},{"key":"932_CR65","doi-asserted-by":"publisher","first-page":"4532","DOI":"10.1158\/1078-0432.CCR-13-0657","volume":"19","author":"S Cardarella","year":"2013","unstructured":"Cardarella S, Ogino A, Nishino M et al (2013) Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res 19:4532\u20134540. https:\/\/doi.org\/10.1158\/1078-0432.CCR-13-0657","journal-title":"Clin Cancer Res"},{"key":"932_CR66","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/S1470-2045(16)30146-2","volume":"17","author":"D Planchard","year":"2016","unstructured":"Planchard D, Besse B, Groen HJM et al (2016) Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol 17:984\u2013993. https:\/\/doi.org\/10.1016\/S1470-2045(16)30146-2","journal-title":"Lancet Oncol"},{"key":"932_CR67","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1097\/JTO.0000000000000625","volume":"10","author":"O Gautschi","year":"2015","unstructured":"Gautschi O, Milia J, Cabarrou B et al (2015) Targeted therapy for patients with BRAF-mutant lung cancer: results from the european EURAF Cohort. J Thorac Oncol 10:1451\u20131457. https:\/\/doi.org\/10.1097\/JTO.0000000000000625","journal-title":"J Thorac Oncol"},{"key":"932_CR68","doi-asserted-by":"publisher","first-page":"9755","DOI":"10.1038\/srep09755","volume":"5","author":"JS Jang","year":"2015","unstructured":"Jang JS, Lee A, Li J et al (2015) Common oncogene mutations and novel SND1-BRAF transcript fusion in lung adenocarcinoma from never smokers. Sci Rep 5:9755. https:\/\/doi.org\/10.1038\/srep09755","journal-title":"Sci Rep"},{"key":"932_CR69","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1200\/JCO.2011.35.9638","volume":"29","author":"A Marchetti","year":"2011","unstructured":"Marchetti A, Felicioni L, Malatesta S et al (2011) Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J Clin Oncol 29:3574\u20133579. https:\/\/doi.org\/10.1200\/JCO.2011.35.9638","journal-title":"J Clin Oncol"},{"key":"932_CR70","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.cell.2012.08.029","volume":"150","author":"M Imielinski","year":"2012","unstructured":"Imielinski M, Berger AH, Hammerman PS et al (2012) Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell 150:1107\u20131120. https:\/\/doi.org\/10.1016\/j.cell.2012.08.029","journal-title":"Cell"},{"key":"932_CR71","doi-asserted-by":"publisher","first-page":"103008","DOI":"10.1016\/j.critrevonc.2020.103008","volume":"152","author":"D Frisone","year":"2020","unstructured":"Frisone D, Friedlaender A, Malapelle U et al (2020) A BRAF new world. Crit Rev Oncol Hematol 152:103008. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103008","journal-title":"Crit Rev Oncol Hematol"},{"key":"932_CR72","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3389\/fonc.2019.00166","volume":"9","author":"A Friedlaender","year":"2019","unstructured":"Friedlaender A, Banna G, Malapelle U et al (2019) Next generation sequencing and genetic alterations in squamous cell lung carcinoma: Where are we today? Front Oncol 9:166. https:\/\/doi.org\/10.3389\/fonc.2019.00166","journal-title":"Front Oncol"},{"key":"932_CR73","unstructured":"NCCN Guidelines. Non-Small Cell Lung Cancer Version 5 (2026) https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1450. Accessed 22 April 2026"},{"key":"932_CR74","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.lungcan.2017.02.024","volume":"108","author":"SH McEvoy","year":"2017","unstructured":"McEvoy SH, Halpenny DF, Viteri-Jusu\u00e9 A et al (2017) Investigation of patterns of nodal metastases in BRAF mutant lung cancer. Lung Cancer 108:62\u201365. https:\/\/doi.org\/10.1016\/j.lungcan.2017.02.024","journal-title":"Lung Cancer"},{"key":"932_CR75","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.jtho.2018.04.024","volume":"13","author":"E Dudnik","year":"2018","unstructured":"Dudnik E, Peled N, Nechushtan H et al (2018) BRAF mutant lung cancer: programmed death ligand 1 expression, tumor mutational burden, microsatellite instability status, and response to immune check-point inhibitors. J Thorac Oncol 13:1128\u20131137. https:\/\/doi.org\/10.1016\/j.jtho.2018.04.024","journal-title":"J Thorac Oncol"},{"key":"932_CR76","doi-asserted-by":"publisher","first-page":"107865","DOI":"10.1016\/j.lungcan.2024.107865","volume":"194","author":"M Provencio","year":"2024","unstructured":"Provencio M, Robado de Lope L, Serna-Blasco R et al (2024) BRAF mutational status is associated with survival outcomes in locally advanced resectable and metastatic NSCLC. Lung Cancer 194:107865. https:\/\/doi.org\/10.1016\/j.lungcan.2024.107865","journal-title":"Lung Cancer"},{"key":"932_CR77","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMoa1502309","volume":"373","author":"DM Hyman","year":"2015","unstructured":"Hyman DM, Puzanov I, Subbiah V et al (2015) Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med 373:726\u2013736. https:\/\/doi.org\/10.1056\/NEJMoa1502309","journal-title":"N Engl J Med"},{"key":"932_CR78","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(16)00077-2","author":"D Planchard","year":"2016","unstructured":"Planchard D, Kim TM, Mazieres J et al (2016) Dabrafenib in patients with BRAF(V600E)-positive advanced non\u2010small\u2010cell lung cancer: a single\u2010arm, multicentre, open\u2010label, phase 2 trial. Lancet Oncol https:\/\/doi.org\/10.1016\/s1470-2045(16)00077-2","journal-title":"Lancet Oncol"},{"key":"932_CR79","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00266","author":"V Subbiah","year":"2019","unstructured":"Subbiah V, Gervais R, Riely G et al (2019) Efficacy of vemurafenib in patients with non-small-cell lung cancer with BRAF V600 mutation: an open-label, single-arm cohort of the histology-independent VE-BASKET study. JCO Precis Oncol https:\/\/doi.org\/10.1200\/PO.18.00266. PO.18.00266","journal-title":"JCO Precis Oncol"},{"key":"932_CR80","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.annonc.2019.10.022","volume":"31","author":"J Mazieres","year":"2020","unstructured":"Mazieres J, Cropet C, Montan\u00e9 L et al (2020) Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations. Ann Oncol 31:289\u2013294. https:\/\/doi.org\/10.1016\/j.annonc.2019.10.022","journal-title":"Ann Oncol"},{"key":"932_CR81","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","volume":"18","author":"D Planchard","year":"2017","unstructured":"Planchard D, Smit EF, Groen HJM et al (2017) Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. Lancet Oncol 18:1307\u20131316. https:\/\/doi.org\/10.1016\/S1470-2045(17)30679-4","journal-title":"Lancet Oncol"},{"key":"932_CR82","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jtho.2021.08.011","volume":"17","author":"D Planchard","year":"2022","unstructured":"Planchard D, Besse B, Groen HJM et al (2022) Phase 2 study of dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic NSCLC: updated 5-year survival rates and genomic analysis. J Thorac Oncol 17:103\u2013115. https:\/\/doi.org\/10.1016\/j.jtho.2021.08.011","journal-title":"J Thorac Oncol"},{"key":"932_CR83","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1200\/JCO.23.00774","volume":"41","author":"GJ Riely","year":"2024","unstructured":"Riely GJ, Smit EF, Ahn MJ et al (2024) Phase II, open-label study of encorafenib plus binimetinib in patients with BRAFV600-mutant metastatic non-small-cell lung cancer. J Clin Oncol 41:3700\u20133711. https:\/\/doi.org\/10.1200\/JCO.23.00774","journal-title":"J Clin Oncol"},{"key":"932_CR84","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.jtho.2025.05.023","volume":"20","author":"GJ Riely","year":"2025","unstructured":"Riely GJ, Ahn MJ, Clarke JM et al (2025) Updated efficacy and safety from the phase 2 PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic NSCLC-A brief report. J Thorac Oncol 20:1538\u20131547. https:\/\/doi.org\/10.1016\/j.jtho.2025.05.023","journal-title":"J Thorac Oncol"},{"key":"932_CR85","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1200\/JCO-25-02023","volume":"43","author":"ML Johnson","year":"2025","unstructured":"Johnson ML, Smit EF, Felip E et al (2025) Updated overall survival analysis from the phase II PHAROS study of encorafenib plus binimetinib in patients with BRAF V600E-mutant metastatic non-small cell lung cancer. J Clin Oncol 43:3706\u20133713. https:\/\/doi.org\/10.1200\/JCO-25-02023","journal-title":"J Clin Oncol"},{"key":"932_CR86","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","volume":"364","author":"PB Chapman","year":"2011","unstructured":"Chapman PB, Hauschild A, Robert C et al (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507\u20132516. https:\/\/doi.org\/10.1056\/NEJMoa1103782","journal-title":"N Engl J Med"},{"key":"932_CR87","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1056\/NEJMoa1412690","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Karaszewska B, Schachter J et al (2015) Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 372:30\u201339. https:\/\/doi.org\/10.1056\/NEJMoa1412690","journal-title":"N Engl J Med"},{"key":"932_CR88","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ et al (2018) Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 19:1315\u20131327. https:\/\/doi.org\/10.1016\/S1470-2045(18)30497-2","journal-title":"Lancet Oncol"},{"key":"932_CR89","doi-asserted-by":"publisher","first-page":"106051","DOI":"10.1016\/j.esmoop.2025.106051","volume":"11","author":"D Planchard","year":"2026","unstructured":"Planchard D, Mazi\u00e8res J, Grouin JM et al (2026) Encorafenib plus binimetinib versus dabrafenib plus trametinib for the first-line treatment of patients with BRAFV600E-mutant metastatic non-small cell lung cancer: a matching-adjusted indirect treatment comparison. ESMO Open 11:106051. https:\/\/doi.org\/10.1016\/j.esmoop.2025.106051","journal-title":"ESMO Open"},{"key":"932_CR90","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s12967-017-1278-5","volume":"15","author":"PA Ascierto","year":"2017","unstructured":"Ascierto PA, McArthur GA (2017) Checkpoint inhibitors in melanoma and early phase development in solid tumors: What\u2019s the future? J Transl Med 15:173. https:\/\/doi.org\/10.1186\/s12967-017-1278-5","journal-title":"J Transl Med"},{"key":"932_CR91","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1111\/1759-7714.13346","volume":"11","author":"H Ishii","year":"2020","unstructured":"Ishii H, Azuma K, Kawahara A et al (2020) Predictive value of CD73 expression for the efficacy of immune checkpoint inhibitors in NSCLC. Thorac Cancer 11:950\u2013955. https:\/\/doi.org\/10.1111\/1759-7714.13346","journal-title":"Thorac Cancer"},{"key":"932_CR92","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1158\/1078-0432.CCR-12-1630","volume":"19","author":"DT Frederick","year":"2013","unstructured":"Frederick DT, Piris A, Cogdill AP et al (2013) BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res 19:1225\u20131231. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-1630","journal-title":"Clin Cancer Res"},{"key":"932_CR93","doi-asserted-by":"publisher","first-page":"279ra41","DOI":"10.1126\/scitranslmed.aaa4691","volume":"7","author":"S Hu-Lieskovan","year":"2015","unstructured":"Hu-Lieskovan S, Mok S, Homet Moreno B et al (2015) Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med 7:279ra41. https:\/\/doi.org\/10.1126\/scitranslmed.aaa4691","journal-title":"Sci Transl Med"},{"key":"932_CR94","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387:1540\u20131550. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7","journal-title":"Lancet"},{"key":"932_CR95","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1093\/annonc\/mdz167","volume":"30","author":"J Mazieres","year":"2019","unstructured":"Mazieres J, Drilon A, Lusque A et al (2019) Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol 30:1321\u20131328. https:\/\/doi.org\/10.1093\/annonc\/mdz167","journal-title":"Ann Oncol"},{"key":"932_CR96","doi-asserted-by":"publisher","first-page":"e002891","DOI":"10.1136\/jitc-2021-002891","volume":"9","author":"MV Negrao","year":"2021","unstructured":"Negrao MV, Skoulidis F, Montesion M et al (2021) Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer 9:e002891. https:\/\/doi.org\/10.1136\/jitc-2021-002891","journal-title":"J Immunother Cancer"},{"key":"932_CR97","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/S1470-2045(25)00409-7","volume":"26","author":"A Di Federico","year":"2025","unstructured":"Di Federico A, Wang K, Chen MF et al (2025) First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study. Lancet Oncol 26:1357\u20131369. https:\/\/doi.org\/10.1016\/S1470-2045(25)00409-7","journal-title":"Lancet Oncol"},{"key":"932_CR98","doi-asserted-by":"publisher","first-page":"103531","DOI":"10.1016\/j.jtho.2025.12.001","volume":"21","author":"S Ortiz-Cuaran","year":"2026","unstructured":"Ortiz-Cuaran S, Dupriez L, Nicq C et al (2026) Biology and clinical management of non-V600 BRAF alterations in NSCLC. J Thorac Oncol 21:103531. https:\/\/doi.org\/10.1016\/j.jtho.2025.12.001","journal-title":"J Thorac Oncol"},{"key":"932_CR99","doi-asserted-by":"publisher","first-page":"160","DOI":"10.21037\/jtd-2025-aw-2202","volume":"18","author":"S Hao","year":"2026","unstructured":"Hao S, Zhao S, Shi L (2026) Targeting rare oncogenic mutations in resectable non-small cell lung cancer: emerging perioperative strategies. J Thorac Dis 18:160. https:\/\/doi.org\/10.21037\/jtd-2025-aw-2202","journal-title":"J Thorac Dis"},{"key":"932_CR100","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","volume":"36","author":"KC Arbour","year":"2018","unstructured":"Arbour KC, Mezquita L, Long N (2018) Impact of baseline steroids on efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in patients with non-small-cell lung cancer. J Clin Oncol 36:2872\u20132878. https:\/\/doi.org\/10.1200\/JCO.2018.79.0006","journal-title":"J Clin Oncol"},{"key":"932_CR101","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.lungcan.2014.05.009","volume":"85","author":"SD Robinson","year":"2014","unstructured":"Robinson SD, O\u2019Shaughnessy JA, Cowey CL et al (2014) BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. Lung Cancer 85:326\u2013. https:\/\/doi.org\/10.1016\/j.lungcan.2014.05.009. \u200930","journal-title":"Lung Cancer"},{"key":"932_CR102","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1111\/jcpt.13489","volume":"47","author":"D Li","year":"2022","unstructured":"Li D, Song Z, Dong B et al (2022) Advances in targeted therapy in non-small cell lung cancer with actionable mutations and leptomeningeal metastasis. J Clin Pharm Ther 47:24\u201332. https:\/\/doi.org\/10.1111\/jcpt.13489","journal-title":"J Clin Pharm Ther"},{"key":"932_CR103","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1200\/JCO-25-01062","volume":"43","author":"DH Owen","year":"2025","unstructured":"Owen DH, Halmos B, Puri S et al (2025) Therapy for stage IV non-small cell lung cancer without driver alterations: ASCO living guideline, Version 2025.1. J Clin Oncol 43:e45\u2013e58. https:\/\/doi.org\/10.1200\/JCO-25-01062","journal-title":"J Clin Oncol"},{"issue":"5","key":"932_CR104","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1007\/s12094-022-03046-9","volume":"25","author":"D Isla","year":"2023","unstructured":"Isla D, Lozano MD, Paz-Ares L et al (2023) New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology. Clin Transl Oncol 25(5):1252\u20131267. https:\/\/doi.org\/10.1007\/s12094-022-03046-9","journal-title":"Clin Transl Oncol"},{"key":"932_CR105","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1016\/j.jtho.2021.06.017","volume":"16","author":"C Rolfo","year":"2021","unstructured":"Rolfo C, Mack P, Scagliotti GV et al (2021) Liquid biopsy for advanced NSCLC: a consensus statement from the International Association for the Study of Lung Cancer. J Thorac Oncol 16:1647\u20131662. https:\/\/doi.org\/10.1016\/j.jtho.2021.06.017","journal-title":"J Thorac Oncol"},{"key":"932_CR106","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.3390\/jpm12111874","volume":"12","author":"GM Fadda","year":"2022","unstructured":"Fadda GM, Lobrano R, Casula M et al (2022) Liquid biopsy in the oncological management of a histologically undiagnosed lung carcinoma: a case report. J Pers Med 12:1874. https:\/\/doi.org\/10.3390\/jpm12111874","journal-title":"J Pers Med"},{"key":"932_CR107","doi-asserted-by":"publisher","first-page":"6410","DOI":"10.3390\/ijms24076410","volume":"24","author":"M Casula","year":"2023","unstructured":"Casula M, Pisano M, Paliogiannis P et al (2023) Comparison between three different techniques for the detection of EGFR mutations in liquid biopsies of patients with advanced stage lung adenocarcinoma. Int J Mol Sci 24:6410. https:\/\/doi.org\/10.3390\/ijms24076410","journal-title":"Int J Mol Sci"},{"key":"932_CR108","doi-asserted-by":"publisher","first-page":"100301","DOI":"10.1016\/j.jlb.2025.100301","volume":"8","author":"N Fusco","year":"2025","unstructured":"Fusco N, Venetis K, Pepe F et al (2025) International society of liquid biopsy (ISLB) perspective on minimal requirements for ctDNA testing in solid tumors. J Liq Biopsy 8:100301. https:\/\/doi.org\/10.1016\/j.jlb.2025.100301","journal-title":"J Liq Biopsy"},{"key":"932_CR109","doi-asserted-by":"publisher","first-page":"7202","DOI":"10.1158\/1078-0432.CCR-18-2779","volume":"25","author":"VE Wang","year":"2019","unstructured":"Wang VE, Xue JY, Frederick DT et al (2019) Adaptive resistance to dual BRAF\/MEK inhibition in BRAF-driven tumors through autocrine FGFR pathway activation. Clin Cancer Res 25:7202\u20137217. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-2779","journal-title":"Clin Cancer Res"},{"key":"932_CR110","doi-asserted-by":"publisher","first-page":"882940","DOI":"10.3389\/fonc.2022.882940","volume":"12","author":"L Zhang","year":"2022","unstructured":"Zhang L, Zheng L, Yang Q et al (2022) The evolution of BRAF activation in non-small-cell lung cancer. Front Oncol 12:882940. https:\/\/doi.org\/10.3389\/fonc.2022.882940","journal-title":"Front Oncol"},{"key":"932_CR111","doi-asserted-by":"publisher","first-page":"183","DOI":"10.3389\/fonc.2015.00183","volume":"5","author":"G Palmieri","year":"2015","unstructured":"Palmieri G, Ombra M, Colombino M et al (2015) Multiple molecular pathways in melanomagenesis: characterization of therapeutic targets. Front Oncol 5:183. https:\/\/doi.org\/10.3389\/fonc.2015.00183","journal-title":"Front Oncol"},{"key":"932_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.03.025","author":"F Facchinetti","year":"2020","unstructured":"Facchinetti F, Lacroix L, Mezquita L et al (2020) Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAFV600E non-small cell lung cancer. Eur J Cancer. https:\/\/doi.org\/10.1016\/j.ejca.2020.03.025. 132:211\u2010223","journal-title":"Eur J Cancer"},{"key":"932_CR113","doi-asserted-by":"publisher","first-page":"106047","DOI":"10.1016\/j.esmoop.2025.106047","volume":"11","author":"SA Piha-Paul","year":"2026","unstructured":"Piha-Paul SA, De La Fuente M, Iwamoto F et al (2026) Phase I study of ABM-1310 as monotherapy and in combination with cobimetinib for BRAF-mutated advanced solid tumors: safety, efficacy, and dose expansion. ESMO Open 11:106047. https:\/\/doi.org\/10.1016\/j.esmoop.2025.106047","journal-title":"ESMO Open"},{"key":"932_CR114","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12943-025-02489-2","volume":"24","author":"B Chen","year":"2025","unstructured":"Chen B, Zheng X, Wu J et al (2025) Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions. Mol Cancer 24:279. https:\/\/doi.org\/10.1186\/s12943-025-02489-2","journal-title":"Mol Cancer"},{"key":"932_CR115","doi-asserted-by":"publisher","first-page":"7050","DOI":"10.21037\/jtd-23-1015","volume":"15","author":"L Lv","year":"2023","unstructured":"Lv L, Chen W, Chen N et al (2023) Advances of cell therapy in lung cancer: a narrative review. J Thorac Dis 15:7050\u20137062. https:\/\/doi.org\/10.21037\/jtd-23-1015","journal-title":"J Thorac Dis"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-026-00932-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-026-00932-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-026-00932-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:58:40Z","timestamp":1789549120000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-026-00932-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":115,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["932"],"URL":"https:\/\/doi.org\/10.1007\/s00408-026-00932-9","relation":{},"ISSN":["1432-1750"],"issn-type":[{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]},"assertion":[{"value":"9 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"73"}}